COLUMBUS, Ohio – Dr. Steven Devine (43221), director of the Blood and Marrow Transplant program at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), is one of 11 physicians nationwide selected to receive the new NCI-ASCO Cancer Foundation Clinical Investigator Team Leadership Award.
The award, funded by the National Cancer Institute (NCI) and the American Society of Clinical Oncology (ASCO) Cancer Foundation, is designed to provide recognition and funding for mid-level physician scientists who lead cancer research programs at academic cancer centers.
The 11 clinical investigators are being recognized for their exceptional contributions to the advancement of new therapies by establishing effective collaborations with other scientists through their collaborative team science approach within NCI-funded clinical trials. The two-year award provides investigators with $50,000 annually for their leadership roles in clinical trials at NCI-designated cancer centers.
The OSUCCC – James Blood and Marrow Transplant program is one of the largest in the United States and has earned international recognition leading clinical research initiatives in leukemia, lymphoma and multiple myeloma. Devine oversees a 24-bed hospital unit dedicated to blood and marrow transplant patients.
Devine graduated from the University of Massachusetts Medical School and trained in hematology and oncology at the University of Chicago and Emory University. He is a member of the American Society of Hematology, and is on the board of directors of the American Society of Blood and Marrow Transplantation.
The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James (www.jamesline.com) is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only five centers in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.# # #
Medical Center Communications